Tenax Therapeutics

TENX

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Tenax Therapeutics is a small biotech company focused on developing drugs for serious heart and lung conditions. Its lead drug candidate is levosimendan, which it is testing as a treatment for pulmonary hypertension associated with heart failure — a condition where the heart struggles to pump blood properly. The company does not yet sell any approved products and is still in the clinical trial stage.

Tenax makes no product revenue today. It funds its operations through equity raises and other financing, which is common for early-stage biotechs. The company is based in the United States and, with a market cap of roughly $200 million, is considered a micro-cap. Its entire value rests on the success of its drug pipeline, meaning the biggest risk is clinical trial failure — if levosimendan does not meet its endpoints in late-stage trials, the company's prospects would be severely damaged.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-29.6% YoY

YoY Growth Rate

Earnings declining

Insider Activity

3.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~2 years

$118M cash & investments

Quarterly Free Cash Flow

$118M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-43.9%

Weak — -43.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial